During the corresponding time, Profound Medical Corp recorded a revenue increase by 103.62 % year on year, sequentially revenue fell by -10.71 %. While revenue at the Profound Medical Corp 's corporate clients
Profound Medical's Comment on Sales, Marketing and Customers
The company provides products and services to physicians treating prostate diseases, including prostate cancer and benign prostatic hyperplasia (BPH). Its business model includes sales of capital equipment and recurring non-capital equipment, such as single-use devices for each patient, along with related services. The TULSA-PRO system is designed to ablate prostate tissue and is marketed to increase utilization following FDA clearance. The company's market segments include men diagnosed with prostate cancer and BPH in the United States and European Union. Customers and markets referenced include the American Cancer Society and the American Urological Association.
In a significant stride towards bolstering renewable energy development in South Africa, the Copenhagen Infrastructure Partners (CIP) has entered into a strategic partnership with Norfund, the Norwegian Investment Fund for Developing Countries. The collaboration is set to channel USD 75 million into Mulilo, a prominent player in the South African renewable energy sector, marking a pivotal moment in the intersection of finance and sustainability.Mulilo has garnered a reputation for its innovative approach to renewable energy, primarily focusing on solar and wind projects. It operates at the forefront of South Africa’s ambitious efforts to transition to a greener economy, alleviating the persistent energy ch...
Profound Medical s TULSA Reimbursement Elevated to Urology APC Level 7 Under CMS OPPS Final Rule for CY2025 In a significant development for the treatment of prostate diseases, Profound Medical Inc. recently announced that their innovative TULSA procedure has been granted a reimbursement increase to Urology Ambulatory Payment Classification (APC) Level 7 under the Centers for Medicare and Medicaid Services (CMS) Outpatient Prospective Payment System (OPPS) Final Rule for Calendar Year 2025. This elevation highlights TULSA’s growing recognition and potential in the field of urological healthcare.The CMS OPPS Final Rule determines the reimbursement rates for outpatient services provided to Medicare beneficia...
Profound Medical’s Comment on Sales, Marketing and Customers
The company provides products and services to physicians treating prostate diseases, including prostate cancer and benign prostatic hyperplasia (BPH). Its business model includes sales of capital equipment and recurring non-capital equipment, such as single-use devices for each patient, along with related services. The TULSA-PRO system is designed to ablate prostate tissue and is marketed to increase utilization following FDA clearance. The company's market segments include men diagnosed with prostate cancer and BPH in the United States and European Union. Customers and markets referenced include the American Cancer Society and the American Urological Association.
Sources:
Profound Medical Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Profound Medical Corp’s corporate clients.
For your research, we’ve provided 9 tables on Profound Medical Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
96.35 %